Global pharmaceutical consultancy Kantar Health has cited three cancer research study results to be released at ASCO 2012 (June 1-5, 2012, in Chicago) that may change the way certain advanced cancers are treated. Listed below, courtesy of Oncology Business Review (at www.oncbiz.com), are Kantar’s 3 picks for likely most important new findings in oncology. 1. ... read more »
Biotechnology pioneer company Genentech is moving ahead with its latest advance in the treatment of metastatic breast cancer. Data from its newest therapy, TDM-1, will be showcased at the premier annual cancer meeting in America called ASCO (American Society for Clinical Oncology) on June 1-5, 2012 in Chicago. Data is being presented from the pivotal ... read more »
All original content © 2002 - 2013 Imperfect Parent®. Imperfect Parent and Mominatrix are registered trademarks.
The views, opinions and information expressed in articles and blog posts published on imperfectparent.com and all subdomains are those of the authors alone. They do not represent the views or opinions of The Imperfect Parent or its staff, nor do they represent the views or opinions of any entity of, or affiliated with, Imperfect Parent. The Imperfect Parent is designed for entertainment purposes only and is not meant to be a substitute for medical, health, legal, or financial advice from a professional.
Reproduction of material from any of Imperfect Parent's pages without written permission is strictly prohibited.
